Should We Financially Incentivize Interventions to Prevent Postpartum Depression?
BACKGROUND AND PURPOSE:
Value-based payment (VBP) models often rely on preventative services that focus on short term cost containment (see ‘Related ObG Topics’ below for more on VBP)
However, the majority of savings from preventing postpartum depression (PPD) may accrue later in a patient’s journey
Counts et al. (JAMA Network Open, 2022) examined whether sharing 5-year expected savings resulting from reduced PPD incidence may offer stronger incentives for prevention than traditional VBP
Decision analytic model
Simulated cohort of 1000 Medicaid-enrolled pregnant individuals
Cohort designed to be reflective of the demographics characteristics of pregnant individuals receiving Medicaid
Sharing 100% of 1-year actual health care cost saving
Sharing 50% of 5-year estimated health care cost savings with reduced PPD incidence
Health care costs for individuals receiving PPD preventive intervention, and those who were not receiving intervention, were estimated for 2020 to 2025
Over 1 or 5 years postpartum
In a variety of scenarios, e.g., varying rates of Medicaid churn (transitions to a new Medicaid managed care plan, commercial insurance plan, or loss of coverage)
In addition to the primary outcome, the likelihood of the health care payer realizing a positive return on investment if it shared 50% of 5-year expected savings with a clinician up front was also measured
Amount of clinician incentive shared in a VBP model from providing preventive interventions
Estimated 5-year savings with providing preventive interventions for PPD: $734.12 (95% credible interval [CrI], 217.21 to 1235.67) per person
Without health insurance churn, sharing 50% of 5-year expected savings could offer more than double the financial incentives for clinicians to prevent PPD vs traditional short-term VBP
50% of 5-year savings: 367.06 (95% CrI, 108.61 to 617.83)
100% of 1-year savings: 177.74 [95% CrI, 52.66 to 296.60)
There was a high likelihood of positive return for the health care payer: 91%
As health insurance churn increased, clinician incentives from sharing estimated savings decreased
With 50% annual churn: 73% reduction
VBP systems for incentivizing prevention of PPD yielded higher financial incentives for clinicians when savings were shared over 5-years vs standard 1-year models
As health insurance churn increased, the clinician incentives decreased
These results support implementing policy to reduce health insurance churn and implement savings sharing as a method of improving implementation of PPD preventative services
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan